These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 35814263)

  • 1. Review on Characterization, Properties, and Analytical Methods of Cefepime.
    Al Kamaly O
    Int J Anal Chem; 2022; 2022():6909528. PubMed ID: 35814263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Barradell LB; Bryson HM
    Drugs; 1994 Mar; 47(3):471-505. PubMed ID: 7514976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cefepime: a review of its use in the management of hospitalized patients with pneumonia.
    Chapman TM; Perry CM
    Am J Respir Med; 2003; 2(1):75-107. PubMed ID: 14720024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cefepime: a new fourth-generation cephalosporin.
    Okamoto MP; Nakahiro RK; Chin A; Bedikian A; Gill MA
    Am J Hosp Pharm; 1994 Feb; 51(4):463-77; quiz 541-2. PubMed ID: 8017411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the in vitro Activity of Two Fourth-Generation Cephalosporins Against Bacterial Samples Isolated From Patients in Several Brazilian Hospitals.
    Cereda RF; Sader HS; Barth AL; Segura A; Kage R; Novakonski A; Pignatari AC
    Braz J Infect Dis; 1999 Oct; 3(5):189-196. PubMed ID: 11084667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cefepime microbiologic profile and update.
    Kessler RE
    Pediatr Infect Dis J; 2001 Mar; 20(3):331-6. PubMed ID: 11303846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial activity and spectrum investigation of eight broad-spectrum beta-lactam drugs: a 1997 surveillance trial in 102 medical centers in the United States. Cefepime Study Group.
    Jones RN; Pfaller MA; Doern GV; Erwin ME; Hollis RJ
    Diagn Microbiol Infect Dis; 1998 Mar; 30(3):215-28. PubMed ID: 9572029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical applications of a new parenteral antibiotic in the treatment of severe bacterial infections.
    Holloway WJ; Palmer D
    Am J Med; 1996 Jun; 100(6A):52S-59S. PubMed ID: 8678098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of cefepime and cefpirome compared to other third-generation cephem antibiotics against gram-negative nosocomial pathogens.
    Tumah HN
    Pharmazie; 2004 Nov; 59(11):854-8. PubMed ID: 15587586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized study of cefepime versus the combination of gentamicin and mezlocillin as an adjunct to surgical treatment in patients with acute cholecystitis.
    Yellin AE; Berne TV; Appleman MD; Heseltine PN; Gill MA; Okamoto MP; Baker FJ; Holcomb C
    Surg Gynecol Obstet; 1993; 177 Suppl():23-9; discussion 35-40. PubMed ID: 8256188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cefepime versus vancomycin plus netilmicin therapy for continuous ambulatory peritoneal dialysis-associated peritonitis.
    Wong KM; Chan YH; Cheung CY; Chak WL; Choi KS; Leung SH; Leung J; Chau KF; Tsang DN; Li CS
    Am J Kidney Dis; 2001 Jul; 38(1):127-31. PubMed ID: 11431192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dosage cefepime as treatment for serious bacterial infections.
    Giamarellou H
    J Antimicrob Chemother; 1993 Nov; 32 Suppl B():123-32. PubMed ID: 8150755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro evaluation of cefepime and other broad-spectrum beta-lactams against bacteria from Indonesian medical centers. The Indonesia Antimicrobial Resistance Study Group.
    Lewis MT; Biedenbach DJ; Jones RN
    Diagn Microbiol Infect Dis; 1999 Dec; 35(4):285-90. PubMed ID: 10668587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cefepime: a fourth-generation parenteral cephalosporin.
    Wynd MA; Paladino JA
    Ann Pharmacother; 1996 Dec; 30(12):1414-24. PubMed ID: 8968455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the in vitro and in vivo antibacterial activities of cefepime (BMY-28142) with ceftazidime, cefuzonam, cefotaxime and cefmenoxime.
    Masuyoshi S; Hiraoka M; Inoue M; Tomatsu K; Hirano M; Mitsuhashi S
    Drugs Exp Clin Res; 1989; 15(1):1-10. PubMed ID: 2663406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Jones RN; Sader HS; Fritsche TR; Pottumarthy S
    Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cefepime monotherapy for the empirical treatment of fever in granulocytopenic cancer patients.
    Eggimann P; Glauser MP; Aoun M; Meunier F; Calandra T
    J Antimicrob Chemother; 1993 Nov; 32 Suppl B():151-63. PubMed ID: 8150759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cefepime.
    Cunha BA; Gill MV
    Med Clin North Am; 1995 Jul; 79(4):721-32. PubMed ID: 7791419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of cefepime against nosocomial blood culture isolates.
    Qadri SM; Cunha BA; Ueno Y; Abumustafa F; Imambaccus H; Tullo DD; Domenico P
    J Antimicrob Chemother; 1995 Sep; 36(3):531-6. PubMed ID: 8830018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.